Combined effect of C-reactive protein and stavudine on adipogenesis

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 819-829

  Stankov, Metodi V ^a   Schmidt, Reinhold E ^a   Behrens, Georg M N ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADIPONECTIN; C REACTIVE PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; FATTY ACID SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADIPOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID STORAGE; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION;

3T3 CELLS; ADIPOGENESIS; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; MICE; STAVUDINE; ZIDOVUDINE;

EID: 72049107462     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1296     Document Type: Article

References (48)

1. Stankov MV, Behrens GM. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. Endocr Metab Immune Disord Drug Targets 2007; 7:237-249.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867.
3. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25:4-7. (Pubitemid 38032801)
4. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793-1801.
5. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115:1111-1119.
6. Moshage HJ, Roelofs HM, van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988; 155:112-117.
7. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46:1112-1113. (Pubitemid 41316523)
8. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30:113-119. (Pubitemid 46052508)
9. Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51:1131-1137. (Pubitemid 34438360)
10. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596-1600. (Pubitemid 34826630)
11. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23:1835-1839.
12. Aronson D, Bartha P, Zinder O, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004; 21:39-44. (Pubitemid 38168027)
13. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671-674. (Pubitemid 36222590)
14. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004; 27:1680-1687. (Pubitemid 38857444)
15. Yuan G, Chen X, Ma Q, et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 2007; 194:275-281. (Pubitemid 47249666)
16. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004; 9:161-177. (Pubitemid 38560209)
17. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311:372-379. (Pubitemid 37340087)
18. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388. (Pubitemid 32500171)
19. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094-2099. (Pubitemid 33643677)
20. Nolan D, Mallal S. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther 2004; 9:34-40.
21. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338. (Pubitemid 36819847)
22. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626. (Pubitemid 38057108)
23. Stankov MV, Schmidt RE, Behrens GM. Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion. Antimicrob Agents Chemother 2008; 52:2882-2889.
24. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In Krawetz S, Misener S (Editors). Bioinformatics methods and protocols: methods in molecular biology. Totowa: Humana Press 2000; pp 365-386.
25. Gorzelniak K, Janke J, Engeli S, Sharma AM. Validation of endogenous controls for gene expression studies in human adipocytes and preadipocytes. Horm Metab Res 2001; 33:625-627. (Pubitemid 33015967)
26. Spiegelman BM, Farmer SR. Decreases in tubulin and actin gene expression prior to morphological differentiation of 3T3 adipocytes. Cell 1982; 29:53-60.
27. An Z, Wang H, Song P, Zhang M, Geng X, Zou MH. Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem 2007; 282:26793-26801.
28. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1:1458-1461.
29. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136. (Pubitemid 39463677)
30. Stankov MV, Lucke T, Das AM, Schmidt RE, Behrens GM. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir Ther 2007; 12:205-216. (Pubitemid 46569906)
31. Masia M, Bernal E, Padilla S, et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007; 195:167-171. (Pubitemid 47569983)
32. Viengchareun S, Caron M, Auclair M, et al. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 2007; 12:919-929. (Pubitemid 47492561)
33. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12:489-500. (Pubitemid 47041147)
34. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004; 9:911-920. (Pubitemid 40040265)
35. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008; 453:783-787. (Pubitemid 351793777)
36. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031. (Pubitemid 34286541)
37. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301:1045-1050. (Pubitemid 36279218)
38. Lagathu C, Yvan-Charvet L, Bastard JP, et al. Long-term treatment with interleukin-1b induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49:2162-2173. (Pubitemid 44168485)
39. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes 2002; 51:1319-1336. (Pubitemid 34826596)
40. Zhang HH, Kumar S, Barnett AH, Eggo MC. Dexamethasone inhibits tumor necrosis factor-α-induced apoptosis and interleukin-1 β release in human subcutaneous adipocytes and preadipocytes. J Clin Endocrinol Metab 2001; 86:2817-2825. (Pubitemid 32545745)
41. Lefterova MI, Zhang Y, Steger DJ, et al. PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev 2008; 22:2941-2952.
42. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166:480-485.
43. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221:286-289.
44. Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des 2003; 9:1023-1031. (Pubitemid 36443203)
45. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13:84-89. (Pubitemid 36740452)
46. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143:998-1007. (Pubitemid 34164048)
47. Hernandez R, Teruel T, de Alvaro C, Lorenzo M. Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-α induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia 2004; 47:1615-1624. (Pubitemid 39371645)
48. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52:1655-1663. (Pubitemid 36792453)